CNS Pharmaceuticals, Inc.

Nasdaq:CNSP

Pharmaceutical Preparations·HOUSTON, TX

CEO

Levin Rami

CFO

O'Loughlin Steve

Summary Financials

Revenue

—

Adj. EBITDA

-$18.9M

FY 2024

Net Income

-$18.9M

FY 2024

EPS (Diluted)

-$12509.11

FY 2024

Stock Price

$3.18

+8.2%

2026-03-10

52W Range

$2.76 – $55.20

P/E Ratio

-0.0x

Market Cap

$2.0M

Cash

$548,721

FY 2024

Total Debt

$425,990

FY 2022

Net Cash

$122,731

FY 2022

Enterprise Value

$1.8M

Debt / EBITDA

0.0x

FY 2024

EV / EBITDA

-0.1x

Employees

—

Revenue

—

Adj. EBITDA

-$18.9M

FY 2024

Net Income

-$18.9M

FY 2024

EPS (Diluted)

-$12509.11

FY 2024

Stock Price

$3.18

+8.2%

2026-03-10

52W Range

$2.76 – $55.20

P/E Ratio

-0.0x

Market Cap

$2.0M

Cash

$548,721

FY 2024

Total Debt

$425,990

FY 2022

Net Cash

$122,731

FY 2022

Enterprise Value

$1.8M

Debt / EBITDA

0.0x

FY 2024

EV / EBITDA

-0.1x

Employees

—